Financial Performance - Company's operating revenue reached a historical high of 150.14 billion yuan, a year-on-year increase of 6.92%[2] - Non-GAAP net profit attributable to the parent company was 1.96 billion yuan, a year-on-year increase of 13.06%[2] - Operating cash flow reached a record high of 4.748 billion yuan, a year-on-year increase of 19.10%[2] - Revenue for 2023 reached 150.14 billion RMB, a 6.92% increase compared to 2022[27] - Net profit attributable to shareholders in 2023 was 2.17 billion RMB, up 4.27% year-over-year[27] - Operating cash flow increased by 19.10% to 4.75 billion RMB in 2023[27] - Total assets grew by 0.52% to 92.79 billion RMB at the end of 2023[27] - Basic earnings per share rose 7.84% to 0.55 RMB in 2023[28] - Weighted average return on equity (ROE) increased by 0.06 percentage points to 9.04% in 2023[28] - The company achieved operating revenue of 150.14 billion yuan, a year-on-year increase of 6.92%, and net profit attributable to the parent company of 2.174 billion yuan, a year-on-year increase of 4.27%[172] - The company's main business revenue reached 149.981 billion yuan, a year-on-year increase of 6.91%, with a gross profit of 12.049 billion yuan, a year-on-year increase of 10.48%[173] Business Segments and Revenue Growth - The company's pharmaceutical industry self-produced and OEM business sales revenue reached 2.476 billion yuan[4] - The company's total agency brand promotion business (CSO) sales revenue reached 19.584 billion yuan, a year-on-year increase of 52.45%[5] - The company's pharmaceutical total agency brand promotion business sales revenue reached 10.696 billion yuan, a year-on-year increase of 60.82%[5] - The company's medical device total agency brand promotion business sales revenue reached 8.888 billion yuan, a year-on-year increase of 31.44%[5] - Total agency brand promotion business revenue grew 46.01% in 2023, with a 52.45% increase in gross profit[30] - Pharmaceutical new retail business revenue increased by 10.95% in 2023[30] - Digital logistics technology and supply chain solutions revenue grew 28.45% in 2023, with a 49.44% increase in gross profit[30] - Total agency brand promotion business revenue reached 19.584 billion yuan, a year-on-year increase of 46.01%[40] - Pharmaceutical new retail business revenue increased by 10.95% year-on-year[40] - Digital logistics technology and supply chain solutions revenue increased by 28.45% year-on-year[40] - Total agency brand promotion business (CSO) achieved sales revenue of 19.584 billion yuan, a year-on-year increase of 46.01%, with a gross profit of 2.789 billion yuan, up 52.45% year-on-year[43] - Pharmaceutical total agency brand promotion business achieved sales revenue of 10.696 billion yuan, a year-on-year increase of 60.82%, with a gross profit of 2.267 billion yuan, up 54.83% year-on-year[43] - Medical device total agency brand promotion business achieved sales revenue of 8.888 billion yuan, a year-on-year increase of 31.44%, with a gross profit of 522 million yuan, up 42.91% year-on-year[44] - Pharmaceutical industry self-production and OEM business achieved sales revenue of 2.476 billion yuan, with a gross profit margin of 23.84% and a gross profit of 590 million yuan[45] - JiuXin Traditional Chinese Medicine Group achieved self-production sales revenue of 1.2 billion yuan, with a gross profit margin of 25.6% and a gross profit of 307 million yuan[46] - Beijing Jingfeng Pharmaceutical Group achieved revenue of 466 million yuan, with 150+ products in production and 8 drugs passing consistency evaluation[46] - The company introduced 98 new high-quality products, including 2 with sales exceeding 100 million yuan and 10 with sales exceeding 10 million yuan[43] - The company completed the upgrade of the "Quanqing Health" brand and implemented the full-case brand upgrade for Kefei[43] - The company focused on developing large surgical, cardiovascular intervention, and IVD national platform distribution businesses, optimizing logistics systems and digital platforms[44] - The company produced 36,234 batches of traceable herbal pieces, with a total annual output of 8,991.44 tons, achieving full traceability in the herbal medicine supply chain[46] - Product sales revenue reached 1.882 billion yuan, with Jiuxin Traditional Chinese Medicine focusing on high-quality and safe products, offering a wide range of categories including precious herbs, fine drinks, and formula drinks[47] - The company has obtained 10 MAH Class II product registration certificates and 25 Class I product filing certificates, with 173 OEM medical device specifications and 424 drug OEM specifications, enhancing product competitiveness through self-developed and OEM products[47] - The "Wan Dian Jia Meng" (10,000 Store Franchise) plan has achieved significant progress, with 21,192 direct and franchise pharmacies by the end of Q1 2024, covering 31 provinces and 293 cities, and a target of over 30,000 stores by 2025[49] - Franchise pharmacy sales revenue reached 3.48 billion yuan, an 83.25% year-on-year increase, with 3,900 professional pharmacies, dual-channel pharmacies, and hospital-side stores, including 3.3 billion yuan in prescription outflow revenue[49] - B2C e-commerce total agency and sales business achieved 1.215 billion yuan in revenue, a 26.8% year-on-year growth, with rapid expansion on new e-commerce platforms like Douyin and Kuaishou[50] - The company's B2B e-commerce terminal sales channel generated 17.326 billion yuan in revenue, with the Yaojiujiu B2B platform achieving 11.241 billion yuan in self-operated transactions and covering 99% of administrative regions[51] - Retail e-commerce platform business revenue reached 6.085 billion yuan, an 11.47% year-on-year increase, with sales to JD.com and Alibaba's self-operated platforms exceeding 4.24 billion yuan, a 16.69% increase[52] - The company's logistics Bb/BC integrated warehousing and distribution system supports efficient supply chain logistics, enabling "zero inventory" for online and offline customers and sharing 100,000 product specifications[52] - The company has completed the "Bb/BC integrated warehousing and distribution" logistics service system, covering 6 "BC integrated warehouses" in Hubei, Shanghai, Guangdong, Beijing, Tianjin, and Zhejiang, and has upgraded 24 logistics centers to "Bb integrated" operations across 24 provinces[53] - The "Bb integrated project" was recognized as a leading case in digital transformation by the China Listed Companies Association and the "2023 Digital Economy Development Typical Case" by the Securities Daily[53] - The company launched the "New Medical" strategy, targeting the 321,000 clinics/outpatient departments in China, aiming to provide integrated supply chain and operational services to enhance terminal control[56] - The internet medical business achieved revenue of 156 million yuan in the reporting period, with 31 target hospitals connected to the prescription transfer platform[57] - The company is advancing the REITs project, planning to use 3.3 million square meters of pharmaceutical logistics assets as underlying assets, with the first batch of assets being the Wuhan logistics center, covering 172,000 square meters[59] - The company's digital transformation strategy has established a comprehensive digital platform, including ERP, logistics, and financial systems, supporting multiple business scenarios such as retail, new medical, and pharmaceutical distribution[61] - The company's financial shared cloud platform and "Bb integrated project" were selected as digital transformation典型案例 by the China Listed Companies Association in 2022 and 2023, respectively[61] - The company's "Bb/BC integrated warehousing and distribution project" was recognized as a "2023 Digital Economy Development Typical Case" by the Securities Daily[61] - The company's digital transformation projects, including the orthopedic smart service platform and retail digital operation platform, have been optimized and implemented[61] - The company aims to transition from a traditional pharmaceutical commercial enterprise to a technology-driven platform service provider through digital transformation[61] - The company's revenue from hospital markets reached 54.139 billion yuan, a year-on-year increase of 11.32%, with 268,600 medical institutions covered[62] - Revenue from tiered hospitals was 38.751 billion yuan, up 9.41% year-on-year, covering over 80% of tiered hospitals nationwide[62] - Revenue from primary medical institutions was 7.425 billion yuan, a year-on-year increase of 21.33%, covering over 60% of community health centers and township hospitals[63] - Revenue from private medical institutions was 7.963 billion yuan, up 12.19% year-on-year, serving major private medical groups[63] - The medical device segment achieved sales revenue of 32.815 billion yuan, a year-on-year increase of 11.66%, with 247,500 product specifications[63] - The company's orthopedic Chang'e intelligent service platform was completed, enhancing data service capabilities in the medical device field[64] - The traditional Chinese medicine (TCM) segment achieved sales revenue of 4.2 billion yuan, a year-on-year increase of 14.02%, with a gross profit of 776 million yuan[65] - The TCM segment covers 31 provinces and has established over 30 TCM production bases, with 40 varieties on the quality traceability platform[65] - The company partnered with leading domestic and foreign pharmaceutical companies, including Huarun Sanjiu, Yangtze River Pharmaceutical, and Novo Nordisk, to provide full-chain digital services[66] - Collaborations with medical device companies such as Mindray, MicroPort, and Philips enabled rapid supply to terminal markets through B2B/B2C/O2O platforms[66] - The company signed a strategic cooperation agreement with Johnson & Johnson, covering surgical, orthopedic, and interventional solutions, with a total value of nearly $500 million[67] - The company's logistics system for the "i Maotai" digital marketing platform achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million[68] - The company's logistics subsidiary, Jiuzhou Logistics, was recognized as one of Maotai Group's 23 strategic suppliers, standing out from over 2,000 suppliers[68] - The company's BC integrated warehouse in Hangzhou achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million, while the Tianjin warehouse achieved a peak daily order volume of 20,000 and a peak monthly order volume of 350,000[68] - The company's logistics subsidiary, Jiuzhou Cloud Intelligence, completed a large-scale modern high-end intelligent pharmaceutical warehousing and logistics center project for Shandong Yiyang Health Group[69] - The company signed a memorandum of cooperation with Vietnam Airlines Logistics and Vietnam International Service and Trade Investment to collaborate on logistics information technology and supply chain solutions[70] - The company held the "2023 Jiuzhoutong Financial Institutions Seminar," inviting 32 major financial institutions to discuss future cooperation directions, including expanding credit lines and innovating credit products[71] - The company formed a joint venture, Hubei Jiuzhou Pharmaceutical Supply Chain Co., Ltd., to promote the development of the pharmaceutical supply chain industry in Hubei Province[73] - The company signed a strategic cooperation agreement with Tencent Health to upgrade digital management services, financial payment services, and business intelligence services[74] - The company established a joint artificial intelligence laboratory with Peking University Wuhan Artificial Intelligence Research Institute to enhance digital management and intelligent supply chain systems[74] - The company donated a total of over 3.4 million yuan to support education in 2023, including the construction of the Egret Kindergarten in Ulanhot, Inner Mongolia[75] - The company's 2022 ESG report was rated "A" by Wind ESG and ranked 2nd in the pharmaceutical business category in the 2023 Huazheng ESG rating[75] - The company donated automatic external defibrillators worth over 180,000 yuan to the Red Cross Society of Yingcheng City, Hubei Province, installed in 12 public places with high foot traffic[75] - The company actively participated in disaster relief efforts, organizing donations for the July 2023 floods in Beijing-Tianjin-Hebei and the December 2023 earthquake in Gansu[75] - The company was awarded the "Charitable Donation Enterprise" honor at the first Hubei Charity Awards in September 2023[75] - The "Opinions of the CPC Central Committee and the State Council on Promoting the Development and Growth of the Private Economy" (31 measures) was issued in July 2023, providing strong policy support for private enterprises like the company[76] - In November 2023, eight government departments jointly issued the "Notice on Strengthening Financial Support Measures to Promote the Development and Growth of the Private Economy", proposing 25 specific measures to support private enterprises[79] - The company, as a leading private enterprise in the pharmaceutical distribution industry, will benefit from the financial support policies, which will reduce financing costs and expand financing channels[80] - By 2025, the national and provincial centralized drug procurement is expected to cover more than 500 varieties[81] - The company's sales revenue in public hospitals has achieved a compound annual growth rate of 10.58% over the past three years, with the number of effective customers rapidly increasing to 13,800[85] - Over 70% of the company's existing business is in pharmacies and third-tier markets, benefiting from the outflow of hospital prescriptions and the flow of chronic disease medications to third-tier markets[85] - The company has actively promoted real-world data research on innovative drugs in private hospitals, fostering collaboration opportunities with innovative drug companies[85] - The "dual-channel" policy has been implemented nationwide, covering 2,612 drugs, with reimbursement ratios mostly ranging from 70% to 80%[88] - The company has expanded its business coverage in public hospitals, significantly benefiting from the centralized procurement policy[85] - The company has leveraged its supply chain advantages to secure distribution rights for centralized procurement products and opportunities for total agency promotion in the out-of-hospital market[86] - The company has been actively promoting the development of innovative drugs in private hospitals, enhancing collaboration with innovative drug companies[85] - The company has seen steady growth in sales scale in private hospitals through improved logistics management and supply chain services[85] - The company has capitalized on the expansion of the retail market due to the "dual-channel" and "outpatient coordination" policies[87] - The company has benefited from the dynamic adjustment of the number of drugs included in the "dual-channel" management, with the minimum number being 169 and the maximum being 529[88] - The number of "dual-channel" pharmacies in Shandong Province is expected to exceed 700 by the end of September 2023, with a fund payment ratio of around 70% and no less than 85% for primary medical institutions[89] - By the end of Q1 2024, the company has expanded its directly operated and franchised pharmacies to 21,192, with 3,900 specialty pharmacies, dual-channel pharmacies, and hospital-adjacent stores (including franchised stores)[91] - The company's Good Pharmacist pharmacies in Wuhan have been included in outpatient统筹 management, benefiting from policies such as "outpatient统筹," "dual-channel," and "seven unifications"[91] - The "clinic filing system" was implemented nationwide in 2023, leading to a potential rapid increase in the number of clinics in China[92] - The number of clinics in China reached 321,000 by the end of 2022, with 59,848 new clinics registered in the past year, a 75% increase year-on-year[93] - The clinic medication market in China is growing at a double-digit rate annually, with a market size approaching 200 billion yuan[93] - Jiuzhou Tong's "New Medical" strategy focuses on building a "Digital Medical + Supply Chain" industrial service platform targeting clinic customers, leveraging its strong supply chain capabilities and advanced information management systems[94] - The strategy includes a smart clinic solution combining auxiliary diagnosis systems, ERP systems, patient management systems, and doctor management systems to improve clinic operational efficiency[94] - Jiuzhou Tong aims to provide a turnkey solution for new clinics and drive business growth by integrating upstream supplier resources in specialized fields such as dentistry, medical aesthetics, and traditional Chinese medicine[94] - China's infrastructure REITs market has seen a series of supportive policies since the pilot program was officially launched in April 2020[95][96] - Key policy milestones include the "Guidelines for Public Offering of Infrastructure Securities Investment Funds (Trial)" in August 2020 and the "14th Five-Year Plan" in March 2021, which emphasized the healthy development of infrastructure REITs[97] - The "Notice on Further Improving the Pilot Work of Infrastructure REITs" in July 2021 highlighted the importance of project quality and long-term healthy development of infrastructure REITs[97] - In January 2022, the Ministry of Finance and the State Taxation Administration introduced tax incentives for REITs, allowing deferred taxation on asset transactions or equity acquisitions during the establishment phase[97] - The "Opinions on Further Revitalizing Existing Assets and Expanding Effective Investment" in May 2022 identified key areas for revitalizing existing assets, including infrastructure projects with large scale, good current returns, or growth potential[97] - The "Outline of the Strategic Plan for Expanding Domestic Demand (2022-2035)" in December 2022 proposed the orderly development of infrastructure REITs to form a virtuous cycle between existing assets and new investments[98] - The total scale of infrastructure REITs in China reached 115.6 billion yuan, including 110.5 billion yuan from initial projects and 5.1 billion yuan from expansion projects[101] - The company has approximately 3.3 million square meters of pharmaceutical logistics storage assets and supporting facilities available for REITs issuance[102] - The Chinese government has introduced multiple policies to support the development of REITs, including expanding the scale of REITs issuance and encouraging private investment[99][100][101] - The company's REITs issuance is expected to provide significant equity-based funding, supporting rapid business development[102] - The Chinese government has issued policies to promote the high-quality development of the REITs market,

2024 年第一季度报告 单位：元 币种：人民币 证券代码：600998 证券简称：九州通 九州通医药集团股份有限公司 2024 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信 息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|-------------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 40,472,147,237.18 ...

九州通医药集团股份有限公司 地址：湖北省武汉市汉阳区龙兴西街5号九州通总部大楼 联系电话:027-84683017 客服电话:400-160-0998 传真:027-84451256 九州通医药集团股份有限公司 ESG暨可持续发展报告年九州通 2023 目录 CONTENTS 公司介绍 董事长致辞 关键绩效 01 P002-P008 前 言 关于本报告 更多指标 内容索引 09 P082-P087 附 录 ESG管理 合规经营与风控 恪守商业道德 02 P009-P024 可持续发展治理 应对气候变化 打造绿色供应链 低碳循环运营 03 P025-P034 绿色运营 供应链管理 提升质量管控 重视客户体验 05 P053-P062 全链服务 数字化发展新质力 与上下游共创 07 P071-P078 创新发展 创造多元平等职场 人才吸引与发展 员工福利关怀 职业健康与安全 04 P035-P052 员工成长 支持基层医疗服务 助力乡村振兴 践行社会公益 06 P063-P070 责任公民 加强党建引领 持续丰富家文化 08 P079-P081 党建兴家 前言 关于九州通 | 规模领先 | 实力排名 | 社会影响 ...

九州通医药集团股份有限公司 总经理工作细则 第一章 总 则 第一条 为进一步完善公司法人治理结构，明确总经理的职权、职责，规范总 经理的行为，依据《公司法》和本公司章程，特制定本工作细则。 第二条 公司设总经理 1 名，由董事会聘任或解聘。公司设副总经理若干名， 由董事会聘任或解聘。公司总经理、副总经理、财务总监（财务负责人）、董事会 秘书和业务总裁为公司高级管理人员。 第三条 总经理对董事会负责，组织实施董事会决议，主持公司日常生产经营 和管理工作。 第四条 总经理每届任期三年，连聘可以连任。 （七）决定聘任或者解聘除应由董事会决定聘任或者解聘以外的负责管理人员； （八）董事会授予的其他职权。 第七条 公司副总经理由总经理提名，并经董事会聘任，副总经理协助总经理 开展工作，主要职权如下： 第五条 在公司控股股东、实际控制人单位担任除董事、监事以外其他行政职 务的人员，不得担任公司的高级管理人员。公司高级管理人员仅在公司领薪，不由 控股股东代发薪水。 第二章 总经理的职权 第六条 总经理行使下列职权： （一）主持公司的经营管理工作，组织实施董事会决议，并向董事会报告工作； （二）组织实施公司年度经营计划和投资 ...

九州通医药集团股份有限公司 2023 年度董事会工作报告 2023 年，九州通医药集团股份有限公司（以下简称"公司"或"九州通"） 坚持高质量发展理念，不再片面追求销售收入规模的扩张，而是更加注重经营管 理质量的提升，在持续巩固医药分销业务竞争优势的同时，逐步向医药 CSO、医 药新零售、医药工业等多业态转型升级，并通过数字化、平台化、互联网化建设， 赋能公司业务变革及管理创新；同时，公司治理水平不断提升，公司董事会严格 按照《公司法》《证券法》以及《公司章程》等相关规定，积极开展董事会各项 工作，贯彻落实股东大会的各项决议，保障了公司规范运作和可持续健康发展。 一、2023 年公司重点工作成果 2023 年，公司全力拓展高质量业务，盈利能力不断提升。公司营业收入再 创历史新高，达到 1,501.40 亿元，较上年同期增长 6.92%；扣非归母净利润达 19.60 亿元，较上年同期增长 13.06%，扣非归母净利润的增长快于营业收入的增 长；经营活动现金流再创新高，全年净额达 47.48 亿元，较上年同期增长 19.10%。 在行业的支付环境没有明显改善的情况下，公司的应收账款周转天数为 63 天， 比上年缩 ...

九州通医药集团股份有限公司 独立董事专门会议工作制度 第一章 总 则 第一条 为了进一步完善九州通医药集团股份有限公司（以下简称"公司"） 法人治理结构，促进公司规范运作，依据《公司法》《证券法》《上市公司独立 董事管理办法》等相关法律法规、规范性文件以及《公司章程》的有关规定，结 合公司实际情况，制定本制度。 第二条 独立董事专门会议是独立董事的专门工作机构，按照公司《独立董 事制度》及本工作制度的规定履行职责。 第二章 议事规则 第三条 公司根据需要召开独立董事专门会议，原则上应当至少提前二日通 知全体独立董事。如情况紧急，需要尽快召开独立董事专门会议，经全体独立董 事一致同意，可不受前述通知时限限制。 第四条 会议通知包括以下内容： （一）会议日期和地点； （四）发出通知的日期。 第五条 独立董事专门会议应当由过半数独立董事共同推举一名独立董事 召集和主持；召集人不履职或者不能履职时，两名及以上独立董事可以自行召集 并推举一名代表主持。 第六条 独立董事专门会议在保证全体参会独立董事能够充分沟通并表达意 见的前提下，可以采用现场、视频、电话、邮件、传签或者其他方式召开。 第七条 独立董事专门会议应当由半 ...

九州通医药集团股份有限公司（以下简称"公司"）聘请中审众环会计师事务 所（特殊普通合伙）（以下简称"中审众环"）作为公司2023年度财务及内部控制 审计机构。根据《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交 易所上市公司自律监管指引第1号—规范运作》等有关规定，公司财务与审计委员会 本着勤勉尽责的原则，恪尽职守，认真履职。现将会计师事务所2023年度履职情况 及财务与审计委员会履行监督职责情况汇报如下： 4、执业记录 1、基本信息 中审众环始创于1987年，是全国首批取得国家批准具有从事证券、期货相关 业务资格及金融业务审计资格的大型会计师事务所之一。根据财政部、证监会发 布的从事证券服务业务会计师事务所备案名单，具备股份有限公司发行股份、债 券审计机构的资格。2013年11月，按照国家财政部等有关要求转制为特殊普通合 伙制。注册地址为湖北省武汉市武昌区水果湖街道中北路166号长江产业大厦 17-18层。 2、人员信息 （1）首席合伙人：石文先 （2）2023年末合伙人数量216人、注册会计师数量1,244人、签署过证券服 务业务审计报告的注册会计师人数716人。 3、业务规模 2023年经审计 ...

九州通医药集团股份有限公司 会计师事务所选聘制度 第一章 总 则 （四）具有完成审计任务和确保审计质量的注册会计师； 第一条 为规范九州通医药集团股份有限公司（以下简称"公司"）选聘（包 括新聘、续聘、变更）会计师事务所的行为，切实维护股东利益，提高审计工作 和财务信息的质量，依据《公司法》《证券法》《国有企业、上市公司选聘会计师 事务所管理办法》等法律、行政法规、部门规章、规范性文件和《公司章程》的 有关规定，结合公司实际情况，制定本制度。 第二条 公司选聘会计师事务所对财务会计报告发表审计意见、出具审计报 告，需遵照本制度的规定。公司聘任会计师事务所从事除财务会计报告审计之外 的其他法定审计业务的，可以比照本制度执行。 第三条 公司聘用或解聘会计师事务所，应当由财务与审计委员会审议同意 后，提交董事会审议，并由股东会决定。公司不得在董事会、股东会审议批准前 聘请会计师事务所开展审计业务。 第四条 公司控股股东、实际控制人不得向公司指定会计师事务所，不得干 预财务与审计委员会、董事会及股东会独立履行职责。 第二章 会计师事务所选聘条件 第五条 公司选聘的会计师事务所应当具备下列条件： （一）具备中国证券监督 ...

九州通医药集团股份有限公司 董事会财务与审计委员会2023年度履职情况报告 2023 年，九州通医药集团股份有限公司（以下简称"公司"）董事会财务与 审计委员会根据《上市公司独立董事管理办法》《上海证券交易所上市公司自律 监管指引第 1 号—规范运作》《上海证券交易所股票上市规则》以及《公司章程》 《财务与审计委员会实施细则》等有关规定，本着恪尽职守、勤勉尽责的原则认 真履行了职责，现将 2023 年度履职情况报告如下： 一、财务与审计委员会基本情况 报告期内，公司董事会财务与审计委员会完成换届工作，经公司第六届董事 会第一次会议审议通过，选举产生了第六届董事会财务与审计委员会委员，包括 独立董事汤谷良、非独立董事刘兆年、独立董事曾湘泉、独立董事艾华、独立董 事陆银娣，其中主任委员由具有会计专业资格的独立董事汤谷良担任。 二、财务与审计委员会会议召开情况 2023 年，公司董事会财务与审计委员会共召开了 5 次会议，具体情况如下： 1、2023 年 4 月 22 日，公司召开第五届董事会财务与审计委员会第十五次 会议，审议通过了公司年度财务报告、内部控制评价报告、关联交易、聘任会计 师事务所、会计政策变更等议 ...

关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600998 证券简称：九州通 公告编号：临 2024-025 九州通医药集团股份有限公司 一、本次会计政策变更概述 （一）会计政策变更的原因及变更日期 二、本次会计政策变更具体情况及对公司的影响 （一）本次会计政策变更内容 1、关于流动负债与非流动负债的划分 1 本次会计政策变更，对九州通医药集团股份有限公司（以下简称:公司） 的财务状况、经营成果和现金流量没有重大影响。 本次会计政策变更已经公司第六届董事会第三次会议审议通过，无需提交 公司股东大会审议。 企业在资产负债表日没有将负债清偿推迟至资产负债表日后一年以上的实 质性权利的，该负债应当归类为流动负债。企业是否有行使上述权利的主观可 能性，并不影响负债的流动性划分。对于符合《企业会计准则第 30 号——财务 报表列报》非流动负债划分条件的负债，即使企业有意图或者计划在资产负债 表日后一年内（含一年，下同）提前清偿该负债，或者在资产负债表日至财务 报告批准报出日之间已提前清 ...